Leerink Partners Remains Bullish After Opdivo and HCV Help Drive 3Q Beat for Bristol-Myers Squibb (BMY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Bristol-Myers Squibb Reports Third Quarter Financial Results
October 27, 2015 6:59 AM EDTIncreases Revenues 4% to $4.1 Billion Posts Third Quarter GAAP EPS of $0.42 and Non-GAAP EPS of $0.39 Achieves Significant U.S. Regulatory and Clinical Milestones in Immuno-Oncology Opdivo Approved for Previously-Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Regardless of PD-L1 Expression Opdivo-Yervoy Regimen Approved for Metastatic Melanoma Opdivo Granted Breakthrough Therapy Designation for Metastatic Renal Cell Carcinoma Refines 2015 GAAP EPS Guidance Range to $1.02 - $1.07... More
